Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02086773 · ClinicalTrials.gov registry record · Phase 1

Red Cell Transfusion Goals in Patients With Acute Leukemias

A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Completed
Registry status
Phase 1
Development phase
90
Enrollment target

NCT02086773 is a Phase 1 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 90 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02086773, a Phase 1 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

COMPLETED
Registry status
Phase 1
Development phase
90 participants
Enrollment target

Study Summary

The purpose of this study to determine if a lower hemoglobin transfusion threshold, 7 g/dL, has a safety profile similar to that of the current standard transfusion threshold of 8 g/dL.

Interventions

  • BIOLOGICAL Red blood cell transfusion

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2014-04
Est. Completion 2015-09
Phase Phase 1

What the Registry Record Tells You About NCT02086773

The ClinicalTrials.gov registry entry for NCT02086773 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Red blood cell transfusion is the first listed.

NCT02086773 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02086773 about?

NCT02086773 is a clinical study titled "Red Cell Transfusion Goals in Patients With Acute Leukemias". The purpose of this study to determine if a lower hemoglobin transfusion threshold, 7 g/dL, has a safety profile similar to that of the current standard transfusion threshold of 8 g/dL.

What is the current status of trial NCT02086773?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2014-04. Estimated completion is 2015-09.

What interventions are being tested in trial NCT02086773?

The interventions under investigation include: Red blood cell transfusion (BIOLOGICAL).

Who is sponsoring clinical trial NCT02086773?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.